source
- Lycia Therapeutics raises $317.5 million in IPO as Merck halts sac-TMT trialLycia Therapeutics, founded by Nobel laureate Carolyn Bertozzi, priced its initial public offering at about $317.5 million, bringing total proceeds to roughly $318 million. The offering marks the…
- Personalized mRNA vaccine cuts melanoma recurrence risk by 42% in trialA recent study of a personalized mRNA cancer vaccine showed a 42% reduction in disease recurrence for patients with melanoma compared with the standard of care. The vaccine is tailored to each pat…